Use Of Gene Therapy In The Hematology Drugs Market

Historically, the global hematology drugs market, a major segment in the pharmaceutical drugs industry, grew at a compound annual growth rate (CAGR) of about 6%. The growth during the historic period can be attributed to rising old age population and growing awareness among patients.

The global hematology drugs market size is expected to reach above $50 billion by 2021, growing at a CAGR of more than 6%. Going forward, unhealthy lifestyles leading to anemia and coagulation disorders, along with increased longevity and the launch of pipeline drugs is set to drive the market for hematology drugs.

Find TBRC’s report on the hematology drugs market: https://www.thebusinessresearchcompany.com/report/hematology-drugs-global-market-report-2018

The adoption of gene therapy to treat sickle-cell disease is gradually increasing due to its simplicity, as compared to procedures requiring outside donors. Sickle-cell disease is a type of gene disorder in which a genetic mutation causes hemoglobin in the red blood cells to distort the shape of the cell. This leads to aggregation or clogging of blood resulting in further acute and chronic complications. In gene therapy, a patient serves as his own donor which eliminates the risk of a mismatch. In March 2017, a 13-year old patient with the sickle-cell disease was successfully treated via gene therapy at Necker Children's Hospital in Paris. This gene therapy lasted for 15 months during which the patient’s bone marrow DNA was re-engineered to enable the formation of the right type of red blood cells.

The hematology drugs market is segmented into Blood Products and Anemia And Other Blood Disorder Drugs.

Blood Products segment includes companies that produce blood components such as red cells, platelets, fresh frozen plasma and cryoprecipitate, or plasma derivatives such as albumin and immunoglobulin.

Anemia And Other Blood Disorder Drugs segment includes companies that produce drugs that can be used to prevent and treat anemia and bleeding disorders such as hemophilia and blood clots.

The global hematology drugs market was valued at above $39 billion in 2017. North America was the largest region in the hematology drugs market in 2017, accounting for around 40% market share. The USA was the largest country in the market in 2017, accounting for 32% market share.

Download a sample report: https://www.thebusinessresearchcompany.com/sample.aspx?id=275&type=smp

The top five companies covered are Novo Nordisk A/S, Shire Plc., Bayer AG, Daiichi Sankyo Company, Limited and Biogen Inc. Novo Nordisk was the largest company in the hematology drug market in 2017.

The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company

The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations.